Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00072449 · OUTCOME

Progression-free Survival

Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma · Source last updated 2013-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
days
Interval / dispersion
95% Confidence Interval
Time frame
pt had MRI q3months

What was measured

pt had MRI every 3 months

Groups in this outcome

Rituximab Monotherapy

Rituximab administered at a dose of 375mg/m2 as a single IV infusion every week for up to 8 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Rituximab Monotherapy12

Reported measurements

Source class 1
Values in days · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Rituximab Monotherapy57Not reported29175Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        29
        upper Limit
        175
        value
        57
denoms
  1. counts
    1. group Id
      OG000
      value
      12
    units
    Participants
description
pt had MRI every 3 months
dispersion Type
95% Confidence Interval
groups
  1. description
    Rituximab administered at a dose of 375mg/m2 as a single IV infusion every week for up to 8 weeks
    id
    OG000
    title
    Rituximab Monotherapy
param Type
MEDIAN
reporting Status
POSTED
time Frame
pt had MRI q3months
title
Progression-free Survival
type
SECONDARY
unit Of Measure
days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice